Clinical trials
Recurrent Non-Muscle Invasive Bladder Carcinoma clinical trials
Below are recruiting recurrent non-muscle invasive bladder carcinoma clinical trials, each written for real people, not researchers. We’re tracking 36 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06167356Recruiting
Bladder cancer relapse and quality of life study after TURBT
This study tracks patients with early-stage bladder cancer after surgery (TURBT) to see how often the cancer returns and how it affects your daily life.
Milan, MIAges 18 years+ - NCT06441110RecruitingPhase 3
BCG instillation for medium- to high-risk bladder cancer
This trial tests whether a specific schedule of BCG (a weakened germ that boosts the immune system) placed directly into the bladder is safe and effective for medium- to high-risk bladder cancer that hasn't grown into the muscle. It aims to see if adjusting the standard BCG course can work better for people with a PD-L1-positive tumor.
Fuzhou, FujianAges 18–75 - NCT06378242RecruitingPhase 1/Phase 2
Testing a bladder cancer drug for high-risk NMIBC patients
This trial tests a drug called Disitamab Vedotin, given directly into the bladder, for a type of early bladder cancer (high-risk NMIBC) that has a protein called HER2. It aims to see if this treatment can help avoid more radical surgery.
Guangzhou, GuangdongAges 18–75 - NCT07763197Recruiting
Sample collection for bladder cancer research
This study is collecting blood, urine, and tissue samples from people with high-risk non-muscle invasive bladder cancer to help develop better tests for tracking the disease. By participating, you might help improve future monitoring and treatment decisions.
Austin, TexasAges 18 years+ - NCT07725796RecruitingPhase 1
Study of UGN-501 for recurrent bladder cancer
This study tests an experimental medicine called UGN-501 given directly into the bladder. It is for people whose bladder cancer has come back despite previous treatments, such as BCG therapy. The goal is to find the best dose and see how safe and effective it is.
Queen Creek, ArizonaAges 18 years+ - NCT07726992RecruitingPhase 3
New drug plus BCG for high-risk bladder cancer
This study tests a new immunotherapy drug (SHR-1501) combined with standard BCG therapy for people with a specific type of early bladder cancer (papillary-only, high-risk). The goal is to see if the combination helps prevent cancer from returning better than BCG alone.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06732531RecruitingPhase 1/Phase 2
Testing a new drug for high-risk bladder cancer that came back after BCG
This clinical trial tests a new drug, BH011, for people with high-risk, non-muscle-invasive bladder cancer that has come back or not responded to BCG therapy. The goal is to see if the drug is safe and works well when given directly into the bladder, as an alternative to bladder removal surgery.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06766266RecruitingPhase 1
Irinotecan and Epirubicin for recurring bladder cancer
This trial tests a combination of two chemotherapy drugs (irinotecan and epirubicin) for people whose bladder cancer has come back after prior treatment with a similar drug. The goal is to see if this combination can help shrink or control the cancer.
ChongqingAges 18 years+ - NCT07225127Recruiting
Bladder cancer treatment: therapy vs. surgery
This study compares two standard treatments for high-grade non-muscle-invasive bladder cancer that has come back after initial treatment: medication placed directly into the bladder (intravesical therapy) or bladder removal surgery (cystectomy). The goal is to see which option works better for patients like you.
Tampa, FloridaAges 18 years+ - NCT07206225RecruitingPhase 1
Study of PF-08052667 in non-muscle invasive bladder cancer
This trial tests a new study medicine called PF-08052667 for people with a certain type of bladder cancer that hasn't spread into the muscle. It's for those who have already tried BCG treatment and can't or won't have their bladder removed.
Birmingham, AlabamaAges 18 years+ - NCT06995677RecruitingPhase 2
Study of TYRA-300 for bladder cancer that has not spread into muscle
This trial tests a new pill, TYRA-300, for people with a certain type of early-stage bladder cancer that has a specific genetic change (FGFR3). The goal is to see if it can help by targeting the cancer cells and possibly avoiding more invasive treatments.
Homewood, AlabamaAges 18 years+ - NCT07000084RecruitingPhase 3
Testing gemcitabine with BCG for returning bladder cancer
This trial tests whether adding a chemotherapy drug called gemcitabine to the usual BCG therapy can help prevent bladder cancer from coming back again. If you have had BCG before and your cancer returned, this study might offer a more effective treatment option.
Birmingham, AlabamaAges 18 years+ - NCT06972615RecruitingPhase 2
Bladder chemo plus pembrolizumab for BCG-treated cancer
This trial tests a combination of chemotherapy placed directly into the bladder and an immunotherapy drug called pembrolizumab (given through a vein) for people with high-risk bladder cancer that has not completely responded to or has returned after BCG treatment.
CABAAges 18 years+ - NCT06919965RecruitingPhase 3
TAR-210 vs. standard bladder chemo for high-risk bladder cancer
This trial compares a new drug called TAR-210, given directly into the bladder, to standard chemotherapy for people with a specific type of high-risk bladder cancer that has not invaded muscle. It tests if TAR-210 can be more effective with fewer side effects.
Sun City, ArizonaAges 18 years+ - NCT06833073RecruitingPhase 2
Study of an mRNA vaccine and BCG for bladder cancer
This trial tests an experimental mRNA vaccine (V940) combined with BCG therapy for people with high-risk non-muscle invasive bladder cancer that hasn't spread. It aims to see if the vaccine can help the immune system better fight the cancer.
Bakersfield, CaliforniaAges 18 years+ - NCT06770582RecruitingPhase 2
Adding immunotherapy to radiation for bladder cancer
This trial tests whether adding the immunotherapy drug pembrolizumab to radiation therapy works as well as or better than the usual chemotherapy given with radiation for a type of bladder cancer that has not invaded the muscle. It is for people whose cancer came back or has high-risk features and who would otherwise need to have their bladder removed.
Tucson, ArizonaAges 18 years+ - NCT06733363RecruitingPhase 2
Vegetable diet to prevent bladder cancer return
This trial tests whether a diet rich in cruciferous vegetables (like broccoli, cauliflower, and kale) can help prevent bladder cancer from coming back or getting worse. It is for people with early-stage, non-invasive bladder cancer who live in New York State.
Buffalo, New YorkAges 18 years+ - NCT06637423RecruitingPhase 1/Phase 2
Study of sacituzumab tirumotecan for low-grade bladder cancer
This trial tests a new drug called sacituzumab tirumotecan for people with low-grade bladder cancer that hasn't spread into the bladder muscle. The goal is to see if it can help shrink or control the tumors.
Bakersfield, CaliforniaAges 18 years+ - NCT06545955RecruitingPhase 3
Gene therapy study for high-grade bladder cancer not responding to BCG
This trial tests a gene therapy called nadofaragene firadenovec, given directly into the bladder, either alone or with chemo or immunotherapy. It's for people with high-grade bladder cancer that hasn't gone away after BCG treatment.
Tucson, ArizonaAges 18 years+ - NCT06510374RecruitingPhase 3
Gene therapy vs. observation for intermediate risk bladder cancer
This trial tests a new gene therapy called nadofaragene firadenovec versus just watching and waiting (observation) for people with a specific type of bladder cancer that hasn't grown into the muscle. The goal is to see if the gene therapy can help keep the cancer from coming back.
Mobile, AlabamaAges 18 years+ - NCT06503614RecruitingPhase 2
Durvalumab plus monalizumab for non-invasive bladder cancer
This study tests two immunotherapy drugs (durvalumab and monalizumab) in people with a type of bladder cancer that hasn't spread into the deep muscle layer. The goal is to see if this combination can help control the cancer and prevent it from coming back, possibly avoiding the need for bladder removal.
San Francisco, CaliforniaAges 18 years+ - NCT06319820RecruitingPhase 3
TAR-210 vs standard bladder chemo for FGFR-mutated bladder cancer
This trial compares a new drug, TAR-210, which is placed directly into the bladder, against standard chemotherapy given through a catheter. It is for people with a specific type of bladder cancer that has a change in the FGFR gene.
Little Rock, ArkansasAges 18 years+ - NCT06263153RecruitingPhase 2
Futibatinib and durvalumab before bladder cancer surgery
This trial tests two drugs (futibatinib and durvalumab) given before bladder removal surgery for people with muscle-invasive bladder cancer who cannot take standard cisplatin chemotherapy. The goal is to see if the combination shrinks the tumor and improves outcomes.
Ann Arbor, MichiganAges 18 years+ - NCT06245603Recruiting
Testing Hydeal Cyst with standard treatment for bladder cancer
This study tests a bladder instillation called Hydeal Cyst, given alongside standard BCG or MMC therapy, to see if it helps reduce side effects or improve outcomes for people with non-muscle invasive bladder cancer.
BergamoAges 18 years+
Hear when a new Recurrent Non-Muscle Invasive Bladder Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for recurrent non-muscle invasive bladder carcinoma?
- Yes. Clin2 currently lists 36 recruiting recurrent non-muscle invasive bladder carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a recurrent non-muscle invasive bladder carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a recurrent non-muscle invasive bladder carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Non-Muscle Invasive Bladder Urothelial Carcinoma
- Non-Muscle Invasive Bladder Carcinoma
- Non-muscle Invasive Bladder Cancer With Carcinoma in Situ
- Non Muscle Invasive Bladder Cancer
- Muscle-Invasive Bladder Carcinoma
- Muscle Invasive Bladder Urothelial Carcinoma
- Non-Muscle Invasive Bladder Neoplasms
- High Risk Non-muscle Invasive Bladder Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.